Brainstem and Deep Gray Nuclei Modulate Brain Network Efficiency in Low-risk Term Newborns.

In low-risk term newborns, network analysis of source EEG has identified the hub regions that play an important role in information transfer in the network. However, the network efficiency changes after removing particular hub regions are not yet clear. The resting state 124channel high-density electroencephalography (HD-EEG) was collected from low-risk term newborns within 72 hours after birth.

Report on the European Partnership for Alternative Approaches to Animal Testing (EPAA) "New Approach Methodologies (NAMs) User Forum Kick-Off Workshop".

The European Partnership for Alternative Approaches to Animal Testing (EPAA) held the "New Approach Methodologies (NAMs) User Forum Kick-Off Workshop", at the European Chemicals Agency (ECHA), Helsinki, Finland on 7-8 December 2023. The aim of the User Forum was to gain insight into the regulatory use of NAMs, with a particular reference to Next Generation Risk Assessment (NGRA), for chemical safety assessment. To achieve this, presentations summarised the learnings and experiences of previous EPAA Skin Sensitisation User Forums as well as that of the European Commission's Scientific Committee on Consumer Safety (SCCS).

Progress in Translating Glaucoma Genetics Into the Clinic: A Review.

Precision medicine is paving the way for personalised risk assessment, and its translation into glaucoma clinics holds potential to change current management paradigms. Our understanding of glaucoma's genetic architecture has expanded in recent years, recognising both monogenic and polygenic contributions. Genetic testing within glaucoma populations can provide additional information for clinicians to support decision-making.

The skin allergy risk assessment-integrated chemical environment (SARA-ICE) defined approach to derive points of departure for skin sensitization.

Mechanistically based non-animal methods for assessing skin sensitization hazard have been developed, but are not considered sufficient, individually, to conclusively define the skin sensitization potential or potency of a chemical. This resulted in the development of defined approaches (DAs), as documented in OECD TG 497, for combining information sources in a prescriptive manner to provide a determination of risk or potency. However, there are currently no DAs within OECD TG 497 that can derive a point of departure (POD) for risk assessment.